Following statements made by former U.S. President Donald Trump suggesting potential military action against Colombia, Colombian President Gustavo Petro expressed concerns about a possible threat to his country's sovereignty. Trump, on Sunday, reportedly called Petro "a sick man who makes cocaine to send to the United States," and allegedly stated that military intervention in the South American nation "sounds good."
Petro, a 65-year-old leftist who has had a history of disagreements with Trump, responded by urging Colombians to demonstrate in the streets in defense of their nation. He also issued a series of social media posts and granted an interview to The New York Times, stating, "Well, we are in danger... Because the threat is real. It was made by Trump."
According to an aide who requested anonymity, Petro learned that Trump wished to speak with him while traveling from Cartagena to Bogotá. The phone call took place at the presidential palace as thousands of supporters gathered outside for a rally Petro had organized. The content of the call has not been officially disclosed.
The incident occurred after Trump had authorized the removal of Venezuela's leader, raising concerns in Colombia about a potential shift in U.S. foreign policy towards the region. Petro's reaction reflects the complex relationship between Colombia and the United States, particularly concerning drug policy and political ideologies.
Colombia has historically been a key ally of the United States in the region, receiving significant financial and military aid to combat drug trafficking and insurgent groups. However, Petro's election as Colombia's first leftist president has introduced new tensions into the relationship, particularly regarding his approach to drug policy and his criticism of U.S. foreign policy.
The situation remains fluid, and the long-term implications of Trump's statements and the subsequent phone call are yet to be seen. Further developments are expected as both governments navigate this diplomatic challenge.
Discussion
Join the conversation
Be the first to comment